anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The surgical treatment of acute necrotizing pancreatitis has significantly evolved in recent years with the advent of enhanced imaging techniques and minimally invasive surgery. Various minimally invasive techniques, such as video-assisted retroperitoneal debridement (VARD) and endoscopic transmural necrosectomy (ETN), have been employed in the management of acute necrotizing pancreatitis and are often part of step-up approaches. However, almost all reported step-up approaches only employ a fixed minimally invasive technique prior to open surgery. In contrast, we implemented different minimally invasive techniques during the treatment of acute pancreatitis based on the extent of pancreatic necrosis. For acute necrotizing pancreatitis of the pancreatic bed with or without extension into the left retroperitoneum, we performed mesocolon-preserving laparoscopic necrosectomy for debridment. The quantitative indication for pancreatic debridment in our institute has been described previously. For acute necrotizing pancreatitis of the pancreatic bed with or without extension into the left retroperitoneum, mesocolon-preserving laparoscopic necrosectomy was performed for debridment. To safeguard the mesocolon, the pancreatic bed was entered via the gastrocolic ligament, and the left retroperitoneum was accessed via the lateral peritoneal attachments of the descending colon. Of the 77 patients requiring pancreatic debridment, 41 patients were deemed suitable for mesocolon-preserving laparoscopic necrosectomy by multiple disciplinary team and informed consent was acquired. Of these 41 patients, 27 underwent percutaneous drainage, 10 underwent transluminal drainage, and 2 underwent transluminal necrosectomy prior to laparoscopic necrosectomy. Two patients (4.88%) died of sepsis, three patients (7.32%) required further laparotomic necrosectomy, and five patients (12.20%) required additional percutaneous drainage for residual infection. Three patients (7.32%) experienced duodenal fistula, all of which were cured through non-surgical treatments. Nineteen patients (46.34%) developed pancreatic fistula that persisted for over 3 weeks, with 17 being successfully treated non-surgically. The remaining two patients had pancreatic fistulas that lasted over 3 months; an internal drainage procedure has been planned for them. No patient developed colonic fistula. Mesocolon-preserving laparoscopic necrosectomy proved to be safe and effective in selected patients. It can serve as a supplementary procedure for step-up approaches or as an alternative to other debridment procedures such as VARD, ETN, and laparotomic necrosectomy.
535,014. Vitamins. NATIONAL OIL PRODUCTS CO. Aug. 17, 1939, No. 23771. Convention date, Aug. 30, 1938. [Class 2 (iii)] [Also in Group III] Vitamin-containing oils and concentrates are improved or refined by treating with a de-aerated mixture of de-colorizing carbon and a solvent. The de-aeration may be effected by stirring the carbon-solvent mixture with or without heating, the vapour of the solvent forming a layer which excludes air from the mixture. Colloidal clay may be used with the carbon. Suitable solvents are heptane, ethylene dichloride, trichlorethylene, dichlorethyl ether, chloroform, ether, acetone, isopropanol, methanol, cyclohexane, dioxane, and petroleum ether. The oil to be treated may contain a solvent (preferably the same as that used with the carbon) for instance when fish oil is extracted by a solvent, the extract may be directly treated with the de-aerated carbon-solvent mixture. Oils mentioned are various fish oils, palm oil, wheat germ oil, and oils containing carotene. Examples describe the treatment of various fish-liver oils and of the unsaponifiable fraction of a fish-liver oil.
The study is intended to demonstrate that the NuCel® allograft is effective and safe in promoting bone growth and fusion rate when used in cervical fusion in patients with one, two or three-level diseases of the cervical spine. Sixty subjects will participate in the study at a single clinical site. Participants will be at least 21 years of age. All subjects will have been established with cervical spine disease at one, two or three levels of the cervical spine that requires cervical interbody fusion per the opinion of the treating surgeon. The primary objective is to demonstrate that NuCel® is comparable to autograft bone graft in producing a successful, contiguous fusion at 6 months ±4 weeks post-operative when used in cervical fusion surgery. Success based on findings of cervical CT scan and plain radiographs. Additionally, Visual Analog Scale (VAS), Neck Disability Index (NDI) and patient satisfaction will be used as secondary outcome measures.
About 1.5% of patients undergoing total hip (THA) or total knee arthroplasty (TKA) still develop postoperative venous thromboembolism (VTE), indicating that the current thromboprophylaxis strategy is not optimal. To evaluate the feasibility of therapeutic dosages of direct oral anticoagulants (DOACs) as thromboprophylaxis for high VTE risk patients, we determined the risks of major bleeding and VTE in patients who underwent THA/TKA and were treated with DOACs in therapeutic dosages for atrial fibrillation (AF). We conducted a registry-based cohort study from 2010 to 2018 in Denmark and included AF patients on therapeutic DOACs dose who underwent THA/TKA. AF patients were utilized as proxy since they have a life-long indication for therapeutic anticoagulant medication. The 49-days cumulative incidence (with death as competing risk) of major bleeding was assessed. The same was done for VTE at 49- and 90-days. 1,354 THA and TKA procedures were included. The 49-days cumulative incidence of major bleeding was 1.40% (95%Confidence Interval[CI] 0.88-2.14%). Most bleeding events occurred at the surgical site. The cumulative incidence of VTE at 49-days was 0.59% (95%CI 0.28-1.13%) and 0.74% (95%CI 0.38-1.32%) at 90-days. The incidence of major bleeding in THA/TKA patients on DOACs in therapeutic dosages was in line with previously reported incidences among THA/TKA patients on thromboprophylaxis dosages, while the incidence of VTE was relatively low. These data provide a solid basis for the design of randomized controlled trials to establish the safety and efficacy of therapeutic dosages of DOACs to prevent VTE in high-risk patients.
A compound is provided for increasing the concentration of a parent isoflavone in a subject in vivo. The parent isoflavone has a skeletal structure including a 5 position and a 7 position, a 5 alkyl group, and a 7-hydroxy group with a 7-hydroxy oxygen appended to the 7 position and a 7-hydroxy hydrogen appended to the 7-hydroxy oxygen. The compound includes a substrate having the skeletal structure of the parent isoflavone, with a 5 position and a 7 position corresponding to the 5 and 7 positions respectively of the parent isoflavone. An alkyl group is appended to the 5 position. A promoiety is appended to the 7-hydroxy oxygen of the substrate as a substitute for the 7-hydroxy hydrogen of the parent isoflavone the promoiety and the 7-hydroxy oxygen establishing an alkylcarbonate ester. A related method also is provided.
Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
The invention provides an EGFR targeting polypeptide and application thereof in preparing a targeting drug delivery system for treating EGFR abnormal expression diseases, and belongs to the field of pharmacy. The amino acid sequence of the EGFR targeting polypeptide (named NPTE-1) is shown in SEQ ID NO. 1. The NPTE-1 polypeptide has stronger affinity specificity with EGFR on the cell surface, can be used for preparing a probe for detecting EGFR abnormal expression diseases, and can also be used as an EGFR targeting ligand to realize the targeting effect on EGFR abnormal expression tumor cells. The invention further provides a multifunctional targeting polypeptide (named EMC) with the amino acid sequence shown as SEQ ID NO. 2. The drug-loaded liposome modified by the EMC polypeptide can effectively improve the killing effect of an anticancer drug on tumor cells, reverse the drug resistance of doxorubicin resistant tumors, obviously inhibit the growth of the tumors, prolong the survival time of tumor-bearing mice and have wide application prospects in preparing a targeted drug delivery system for treating EGFR abnormal expression diseases.
PURPOSE:To obtain an antiprotozoal agent, especially an anticoccidial agent comprising a specific compound produced by an actinomyces or its derivative as an active ingredient and having excellent antiprotozoal action and high safety. CONSTITUTION:This antiprotozoal agent, especially an anticoccidial agent comprising a compound of formula I [R<1> is hydroxyl, cyano or carbamoyl; R<2> and R<3> are H or (substituted)lower alkyl] or its salt or a compound of formula II (R<4> is hydroxyl or cyano; R<5> is H or methyl) or its salt as an active ingredient. For example, naphthyridinomycin A, cyanonaphthyridinomycin, SF-1739HP, naphthocyanidine, etc., are cited as the compound of formula I. The naphthyridinomycin A is obtained by culturing an actinomyces Streptomyces sp. HP181 strain (FERM P-13178) and collecting the substance from the resultant culture. The object of this antiprotozoal agent is preferably coccidiosis, malaria, toxoplasmosis, sarcocystosis, etc., among them, the coccidiosis of fowl.
Participants in this group given the option to take part in one of the two forms of relaxation (off study) after they finish their last questionnaire packet. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
Dose quantity and dose frequency of a prescribed drug is extracted from a received text string. A dosage matrix (figure 3) of instances per day against number of days is configured and mapped onto a calendar for recording when the drug should be taken. An indication of consumption or the amount of medication remaining may be presented on a display 116. An audible or visual alarm may be activated when the medication is scheduled to be taken or when the remaining supply is low. An image of a drug box label may be captured (703, figure 7) by a mobile communication device 115, for example a smart phone or tablet, and text may be extracted using optical character recognition, OCR (704, figure 7). Processing circuitry 102 may determine dose quantity and frequency via sentence syntax analysis on an extracted text string. The name, strength and form of medication may be verified using a drug database or library 110. The system allows a patient to provide accurate information to their GP surgery 104 or pharmacy 106 when requesting a repeat prescription using their mobile phone 115.
Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
Participants will be assigned to either Part 1 or Part 2 of this study. Part 1 will be a single-center, double-blind (participants and study personnel will not know the identity of the treatments), randomized (treatment will be assigned by chance), single- and multiple-dose study. There will be 3 groups in Part 1, and the dosing will be as follows: Group A will receive a single oral dose of 30 mg JNJ-38518168 (given as three 10-mg tablets of JNJ-38518168) or placebo (a treatment identical in appearance to JNJ-38518168 but not containing active drug) (Period 1), and multiple oral doses of 30 mg JNJ 38518168 (given as three 10-mg tablets of JNJ-38518168) or matching placebo once daily for 14 consecutive days (Period 2); Group B will receive a single oral dose of 10 mg JNJ-38518168 or placebo (Period 1), and multiple oral doses of 10 mg JNJ-38518168 or placebo once daily for 14 consecutive days (Period 2); and Group C will receive a single oral dose of 3 mg JNJ-38518168 or placebo (Period 1), and multiple oral doses of 3 mg JNJ-38518168 or placebo once daily for 14 consecutive days (Period 2). At least a 20-day washout period will separate the dose administration in Period 1 and the first dose administration of Period 2. The duration of Part 1 will be approximately 78 days. Part 2 of this study will be a single-center, open-label (participants and study personnel will know the identity of the treatments), non-randomized, multiple dose, drug-drug interaction study. Eligible participants will receive a single oral dose of 2.5 mg of midazolam as oral solution on Day 1, three 10-mg tablets of JNJ-38518168 (30 mg) once daily for 14 consecutive days (Day 2 through Day 15); and another single oral dose of 2.5 mg midazolam on Day 15. The duration of Part 2 of the study will be approximately 42 days. Following an interim safety and PK data analysis, one additional treatment group may be studied to evaluate the effect of JNJ-38518168 at a dose lower than 30 mg once daily on the PK of midazolam. During Parts 1 or 2, participants may be admitted to the clinical unit for periods of up to 7 and 18 days, and follow-up return visits to the clinic will also be required.
PROBLEM TO BE SOLVED: To obtain the subject agent and food capable of destroying or suppressing pathogenic bacteria and suppressing the development of a disease caused by the bacteria by including an extract of Fuscoporia obliqua. SOLUTION: This antibacterial agent consists of an extract of Fuscoporia obliqua. The natural and cultured F. obliqua are both effective, but since the natural ones are hard to collect and the yield is small, it is preferable to use the artificially cultured ones. It is preferable to use a saw dust culturing and a liquid culturing method. The extract of the F. obliqua having suitably 10000-1500000, more suitably 10000-100000 molecular weight, has the antibacterial activity. Thus, it can effectively be used as a medicine or by mixing with a food against the pathogenic bacteria (e.g. pathogenic E. coil, pneumobacillus and Pseudomonas aeruginosa).
PURPOSE:To provide the titled activating agent containing the lipid fraction or glycolipid fraction of marine Chlorella as an active component. CONSTITUTION:Powder of marine Chlorella is crushed in the presence of 5-10 times weight of a solvent such as chloroform, methanol, hexane, ethanol, etc., heated for 30min, and stirred. The suspension is filtered, and washed with an aqueous solution of sodium sulfate, etc. to remove the water-soluble extracted component such as sugar. The residue is dehydrated and concentrated under reduced pressure to obtain the objective lipid fraction. The glycolipid fraction is obtained from the lipid fraction e.g. by silica gel column chromatography. An immuno-activating agent having antitumor activity can be produced by using the above fraction as active component. It is administered by integrating the active component in liposome or emulsifying with an emulsifier, and administered by peritoneal infusion or intravenous injection, etc.
PROBLEM TO BE SOLVED: To obtain a powdered cosmetic excellent in application feeling, make-up finish and make-up durability by formulating a specific modified complex excellent in balance between the sliding properties and the adhesion properties and in dispersion in the oil components. SOLUTION: This cosmetic contains a modified complex which is prepared by substantially covering a powder of high masking properties with a regenerated fibroin on its surface and coating the coated layer of the granular complex with an water-soluble polymer. The high masking powder is, for example, titanium oxide, zinc oxide, magnesium oxide or the like. The regenerated fibroin is prepared by using cocoons, raw silk, waste cocoons or viscose, when needed, removing sericin, and dissolving the dried raw material for silk in a solvent and regenerating the material by coagulating the dope. The water-soluble polymer is preferably poly(sodium acrylate). The modified complex is added to a cosmetic in an amount of 30-90 pts.wt. per 100 pts.wt. of the powdery cosmetic.  This powdered cosmetic does not cause deterioration of touch feeling and caking even at a high mixing ratio of the modified complex.
FIELD: medicine, in particular, anesthesiology and reanimatology; applicable in treatment of patients with traumatic shock at early hospital stage. SUBSTANCE: method includes anesthesia, infusion therapy, compensation of blood losses, artificial pulmonary ventilation, medicamentous correction of metabolism disturbances. Intravenous bolus injection of dalargin in a dose of 1 mg is made for stabilization of hemodynamics depending on functional state of blood vascular system with presence of hyperdynamic type of central hemodynamics (cardiac index > 4.2 l (min.sq.m) -1  and peripheral resistance is less than 1200 din.s. -5 ). In case of presence of hypodynamic type of central hemodynamics (cardiac index is less than 2.2 l (min.sq.m) -1  and peripheral resistance is above 2500 din.s.cm -5 ) actovegin in a dose of 2000 mg in 0.9-% solution of sodium chloride of 5-% glucose is injected intravenously at the rate of 20-40 ml/min. EFFECT: higher efficiency. 2 tbl
PROBLEM TO BE SOLVED: To extremely easily produce an activated blood coagulation factor VII having depressed contaminant protein content by treating a plasma fraction containing blood coagulation factor VII by anion exchange chromatography. SOLUTION: A solution containing a blood coagulation factor VII (FVII) is brought into contact with an anion exchange resin and developed. The developed FVII is eluted by partially activating the FVII. The activation rate is preferably <60%. The eluate is left at rest in a solution state to completely activate the non-activated molecule. The buffer solution used in the elution preferably contains Ca<2+> at a concentration of >=0.5mM. The leaving (aging) of the eluate solution is preferably carried out in a solution containing >=0.5mM of Ca<2+> until. >=95% of the FVII is activated. The formation of contaminant substance in the activation process can be suppressed to enable remarkable increase in the yield of the activated product.
An anti-TNF drug administration training booklet were given to patients in the control group and were required to take advantage of the booklet on subcutaneous anti-TNF drug production. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Subcutaneous Anti-TNF Treatment Questionnaire , BASDAI, ASQoL, BASFI scales. At the end of the study (twenty forth week) was applied to all patients.
To provide methods for treating subjects having fibrosis or at risk of developing fibrosis.SOLUTION: Disclosed herein is a method for treating symptoms associated with fibrosis, or preventing or delaying the onset of the symptoms in a subject by administering an effective amount of an antagonist of cadherin 11 to the subject. In embodiments, the fibrosis is dermal fibrosis, scleroderma, non-dermal fibrosis, or pulmonary fibrosis or hepatic fibrosis. The cadherin 11 antagonist is a cadherin 11-binding peptide. The cadherin 11 binding peptide is an anti-cadherin 11 antibody or an antigen binding antibody fragment. The cadherin 11 binding peptide is a cadherin 11 fusion protein. The cadherin binding peptide comprises a full-length cadherin or a fragment thereof. The cadherin 11 antagonist is a cadherin 11 nucleic acid antagonist. The cadherin 11 nucleic acid antagonist is a cadherin 11 siRNA.SELECTED DRAWING: None
Investigators will provide participants with nicotine patches, smoking cessation treatment that will include brief counseling sessions (10-15 minutes each), and text messages sent to their provided study phone throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts. Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. Mobile Health (mHealth) is a general term for the use of mobile phones and other wireless technology in medical care.

The key outcome and hypothesized mechanisms (i.e., lapse and stress) will be measured objectively and automatically using AutoSense. AutoSense is a type of human sensing technology that allows investigators to detect smoking behavior and stress objectively through a chest strap and wrist bands worn by participants. Ecological momentary assessment (EMA) will assess acute precipitants such as negative affect, craving, self-efficacy, motivation, alcohol consumption, etc. Questionnaires will assess other predictors and mechanisms.
The present invention provides methods for promoting generation of heart tissue, and for treating and preventing heart tissue degeneration. Additionally, the present invention provides a therapeutic composition comprising a cyclin-associated agent, and a kit comprising the composition. The present invention further provides a heart tissue cell, a sidepopulation progenitor cell, and a stem cell in which cyclin is augmented. Also provided are cell lines comprising these cells, screening methods using the cell lines, and drugs identified by these methods. The present invention further provides in vitro systems for use in screening candidate drugs for at least one cardiotoxic effect and/or for synergy with cyclin in the treatment and prevention of heart tissue degeneration. Finally, the present invention provides use of a cyclin-associated agent in the generation of heart tissue, and use of a cyclin associated agent in the treatment or prevention of heart tissue degeneration.
The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.